SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.97-3.2%Nov 3 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (6427)5/24/2002 8:39:39 PM
From: RMP  Read Replies (1) of 52153
 
Preview of Barron’s issue of May 27, 2002
Good Medicine.
The broad sell-off in biotechnology stocks may be creating investment opportunities, especially in battered but cash rich companies such as CV Theraputics, Celera Genomics, Intermune and Medarex. Investors can win big if any of these companies drugs prove commercially successful. The big negative: some are bound for extinction. To minimize the risk, own a basket of stocks, Barron's says.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News